Description
Survodutide (BI 456906) is a dual glucagon/GLP‑1 receptor agonist investigated for obesity and related metabolic conditions. Clinical trials used once‑weekly subcutaneous injections with dose‑dependent weight loss during a 20‑week escalation and maintenance thereafter.
Dose Range: 600–4800 mcg weekly (0.6–4.8 mg), escalating as tolerated within trial‑tested range.
Survodutide activates GLP‑1 and glucagon receptors, supporting appetite control and increased energy expenditure. Preclinical work shows dual‑receptor engagement with weight‑lowering effects and a design enabling once‑weekly dosing[11]. Phase 2 trials in obesity used once‑weekly subcutaneous dosing with dose‑dependent weight loss, while studies in diabetes and liver disease further characterize efficacy and safety.
